Nexalin Technologies【NXL】銘柄情報

Nexalin Technologies Inc (NXL) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.4436

( -6.12% )

買値

0.4374

売値

0.4498

出来高

53,465

0.4364 日の範囲 0.4671

0.305 52 週間の範囲 2.00

時価総額

9.13M

前日終値

0.4725

始値

0.4671

時刻

0.4374

最終取引時間

01:25:05

財務取引量

US$ 24,074

VWAP

0.45027

平均取引量 (3 か月)

US$ 487,368

発行済株式数

20,581,646

配当利回り

PER

-0.76

1 株当たり利益 (EPS)

-0.47

歳入

275.58k

純利益

-8.33M

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to trea... Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas. 詳細を表示

セクター

Healthcare

業界

Medical Equipment & Supplies

ウェブサイト

www.nexalin.com

本社

Houston, United States

設立

Nexalin Technologies Inc is listed in the Healthcare sector of the ナスダック市場 with ticker NXL. The last closing price for Nexalin Technologies was US$0.47. Over the last year, Nexalin Technologies shares have traded in a share price range of US$ 0.305 to US$ 2.00.

Nexalin Technologies currently has 20,581,646 shares in issue. The market capitalisation of Nexalin Technologies is US$9.13 million. Nexalin Technologies has a price to earnings ratio (PE ratio) of -0.76.

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Study using Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude...

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further...

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

U.S. House Appropriations Committee report language directs VA to support additional research evaluating...

Form 8-K - Current report

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

HOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NXL) (“Nexalin” or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Publication reports statistically significant improvement in sleep quality following treatment with Nexalin’s...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0864	-16.3018867925	0.53	0.53995	0.4257	299281	0.48441314	CS
4	0.1136	34.4242424242	0.33	0.64	0.305	1489408	0.41745777	CS
12	0.0436	10.9	0.4	0.64	0.305	880276	0.40599379	CS
26	-0.528	-54.3433511733	0.9716	0.9869	0.305	582529	0.45818047	CS
52	-0.7564	-63.0333333333	1.2	2	0.305	1422571	1.38932685	CS
156	-0.4148	-48.3224603914	0.8584	4.4899	0.2528	962882	1.70980835	CS
260	-2.2564	-83.5703703704	2.7	4.4899	0.2528	803021	1.7011344	CS